H Koot1, B M Hogema2, M Koot3, M Molier1, H L Zaaijer4. 1. Department of Blood-Borne Infections, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands. 2. Department of Blood-Borne Infections, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands; Department of Virus Diagnostic Services, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands. 3. Department of Virus Diagnostic Services, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands. 4. Department of Blood-Borne Infections, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands; Medical Microbiology (CINIMA), Academic Medical Center, Amsterdam, The Netherlands. Electronic address: h.l.zaaijer@amc.uva.nl.
Abstract
BACKGROUND AND OBJECTIVE: In several Western countries, silent endemic hepatitis E virus (HEV) infection is common among blood donors. Immunocompromised persons may develop chronic hepatitis E, but the relevance of endemic HEV for immunocompetent persons remains largely unknown. We investigated the immune status and travel history in cases of hepatitis E in the Netherlands. STUDY DESIGN: Between January 2009 and May 2014, physicians throughout the Netherlands submitted samples from 4067 hepatitis patients to Sanquin Diagnostic Services for HEV antibody testing. For the 144 patients testing positive for HEV IgM and HEV RNA, travel behavior and immune status were assessed. Complete information was obtained for 81 patients. RESULTS: Surprisingly, the majority of patients (52/81, 64%) were immunocompetent and did not travel outside Europe. HEV genotyping was obtained for 47 non-traveling patients, all concerned HEV genotype 3. DISCUSSION: Our findings suggest that currently in Western countries the impact of hepatitis E for non-traveling, immunocompetent persons is underestimated. Historically cases of hepatitis A, B and C, but not cases of hepatitis E, are notifiable and warrant preventive measures. However, in parts of Western Europe HEV may have become the most important source of viral hepatitis, in immunocompetent and in immunosuppressed persons. Pending measures against the ongoing transmission of HEV genotype 3 in parts of Europe, physicians should consider hepatitis E in dealing with new hepatitis patients.
BACKGROUND AND OBJECTIVE: In several Western countries, silent endemic hepatitis E virus (HEV) infection is common among blood donors. Immunocompromised persons may develop chronic hepatitis E, but the relevance of endemic HEV for immunocompetent persons remains largely unknown. We investigated the immune status and travel history in cases of hepatitis E in the Netherlands. STUDY DESIGN: Between January 2009 and May 2014, physicians throughout the Netherlands submitted samples from 4067 hepatitispatients to Sanquin Diagnostic Services for HEV antibody testing. For the 144 patients testing positive for HEV IgM and HEV RNA, travel behavior and immune status were assessed. Complete information was obtained for 81 patients. RESULTS: Surprisingly, the majority of patients (52/81, 64%) were immunocompetent and did not travel outside Europe. HEV genotyping was obtained for 47 non-traveling patients, all concerned HEV genotype 3. DISCUSSION: Our findings suggest that currently in Western countries the impact of hepatitis E for non-traveling, immunocompetent persons is underestimated. Historically cases of hepatitis A, B and C, but not cases of hepatitis E, are notifiable and warrant preventive measures. However, in parts of Western Europe HEV may have become the most important source of viral hepatitis, in immunocompetent and in immunosuppressed persons. Pending measures against the ongoing transmission of HEV genotype 3 in parts of Europe, physicians should consider hepatitis E in dealing with new hepatitispatients.
Authors: Martijn D B van de Garde; Suzan D Pas; Guido van der Net; Robert A de Man; Albert D M E Osterhaus; Bart L Haagmans; Andre Boonstra; Thomas Vanwolleghem Journal: J Virol Date: 2016-04-14 Impact factor: 5.103
Authors: Arianne B van Gageldonk-Lafeber; Wim van der Hoek; Floor Borlée; Dick J J Heederik; Sofie H Mooi; Catharina B M Maassen; C Joris Yzermans; Barry Rockx; Lidwien A M Smit; Johan H J Reimerink Journal: BMC Infect Dis Date: 2017-01-05 Impact factor: 3.090
Authors: Lorenzo Subissi; Michael Peeters; Sophie Lamoral; Sofieke Klamer; Vanessa Suin; Steven Van Gucht Journal: Epidemiol Infect Date: 2019-01 Impact factor: 2.451
Authors: Sara A Burt; Jorg Veltman; Renate Hakze-van der Honing; Heike Schmitt; Wim H M van der Poel Journal: Food Environ Virol Date: 2016-05-04 Impact factor: 2.778
Authors: Jeanne Heil; Christian J P A Hoebe; Inge H M van Loo; Jochen W L Cals; Geneviève A F S van Liere; Nicole H T M Dukers-Muijrers Journal: PLoS One Date: 2018-01-25 Impact factor: 3.240